Table 2.
Baseline characteristics of patient and chemotherapy indication and regime given
| No. (%) | |
|---|---|
| Sex | |
| Male | 32 (53.3) |
| Female | 28 (46.7) |
| Age | |
| Median/ Std (y) | 63/13.0 |
| Tumor location | |
| Small bowel | 1 (1.7) |
| Cecum | 4 (6.7) |
| Ascending Colon | 4 (6.7) |
| Hepatic Flexure | 3 (5.0) |
| Transverse Colon | 4 (6.7) |
| Splenic Flexure | 4 (6.7) |
| Descending Colon | 4 (6.7) |
| Rectosigmoid | 26 (43.3) |
| Rectum | 10 (16.7) |
| Microsatellite | |
| Microsatellite stable | 48 (80.0) |
| Microsatellite instability | 2 (3.3) |
| Not available | 10 (16.7) |
| T‐stage | |
| pt1 | 2 (3.3) |
| pt2 | 3 (5.0) |
| pt3 | 26 (43.3) |
| pt4 | 19 (31.7) |
| Not available | 10 (16.7) |
| N‐stage | |
| n0 | 12 (20.0) |
| n1 | 24 (40.0) |
| n2 | 14 (23.3) |
| Not available | 10 (16.7) |
| Chemotherapy indication | |
| Adjuvant | 41 (68.3) |
| Metastatic | 18 (30.0) |
| Neoadjuvant | 1 (1.7) |
| Chemotherapy regime | |
| Single‐agent CAP | 4 (6.7) |
| CAPOX | 45 (75.0) |
| FOLFOX | 10 (16.7) |
| FOLFIRI | 1 (1.7) |